Details

Autor(en) / Beteiligte

• Greiner, Jochen
• Schmitt, Michael
• Li, Li
• Giannopoulos, Krzysztof
• Bosch, Katrin
• Schmitt, Anita
• Dohner, Konstanze
• Schlenk, Richard F.
• Pollack, Jonathan R.
• Dohner, Hartmut
• Bullinger, Lars

Titel

Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches

Ist Teil von

• Blood, 2006-12, Vol.108 (13), p.4109-4117

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• The expression of tumor-associated antigens (TAAs) might play a critical role in the control of minimal residual disease (MRD) in acute myeloid leukemia (AML), and therefore might be associated with clinical outcome in AML. In a DNA microarray analysis of 116 AML samples, we found a significant correlation between high mRNA levels of G250/CA9 and longer overall survival (P = .022), a similar trend with high mRNA levels of PRAME (P = .103), and a hint for RHAMM/HMMR. In contrast, for other TAAs like WT1, TERT, PRTN3, BCL2, and LAMR1, we found no correlation with clinical outcome. High expression of at least 1 of the 3 TAAs, RHAMM/HMMR, PRAME, or G250/CA9, provided the strongest favorable prognostic effect (P = .005). Specific T-cell responses were detected in 8 (47%) of 17 patients with AML in complete remission for RHAMM/HMMR-R3 peptide, in 7 (70%) of 10 for PRAME-P3 peptide, and in 6 (60%) of 10 for newly characterized G250/CA9-G2 peptide, a significant increased immune response compared with patients with AML patients who had refractory disease (P < .001). Furthermore, we could demonstrate specific lysis of T2 cells presenting these epitope peptides. In conclusion, expression of the TAAs RHAMM/HMMR, PRAME, and G250/CA9 can induce strong antileukemic immune responses, possibly enabling MRD control. Thus, these TAAs represent interesting targets for polyvalent immunotherapeutic approaches in AML.